 |
 |

Colistin(Coly-Mycin) in Resistant Bacterial InfectionsA Clinical Appraisal
ELLARD M. YOW, M.D.;
EDWARDO TAN, M.D.;
LOUIS SHANE, M.D.;
SIMON SCHONFELD, M.D.;
HANNA ABU-NASSAR, M.D.
Arch Intern Med. 1961;108(5):664-670.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
Among the new antibiotics investigated clinically in Houston during the past two years, colistin (Coly-Mycin) has been one of the most promising. This antibiotic was isolated in Japan by Yosuo Koyama in 1950 from culture filtrates of Bacillus colistinus, a bacterium closely related to Bacillus polymyxa, the source of the polymyxins. Its pharmacology has been studied in Japan, Italy, France, and, more recently, this country. A summary of the findings of these studies indicates that the chemical, pharmacological, and antimicrobial activity of colistin is closely related to the polymyxins, Clinically, however, colistin causes fewer undesirable side-effects.
Colistin is a complex polypeptide, with an empirical formula of C45H85O10N13 and a molecular weight of 969. Its acid salts are stable in solution even for very long periods; alkaline salts are less stable. It is available as colistin sulfate for oral and ophthalmic use, and as
. . . [Full Text PDF of this Article]
Author Affiliations
HOUSTON, TEXAS
From the Department of Medicine, Baylor University College of Medicine, and The Ben Taub Infectious Disease Research Laboratory, Jefferson Davis Hospital.
Footnotes
Submitted for publication Nov. 14, 1960.
This study was supported by a grant from Warner-Lambert Research Institute.
Coly-mycin M (trade name for sodium colistinmethanesulfonate) is marketed by Warner-Chilcott Laboratories.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|